Alx Oncology Holdings Inc.

Alx Oncology Holdings Inc. is a clinical-stage immuno-oncology company dedicated to developing therapies that enhance immune response against cancer. The company is pioneering the next wave of cancer treatment by focusing on the CD47 checkpoint pathway, a biological mechanism that cancer cells exploit to evade the immune system. Alx Oncology's lead therapeutic candidate is specifically designed to block this pathway, thereby potentiating the body's natural immune defense to recognize and destroy cancer cells. Alx Oncology predominantly impacts the biotechnology and pharmaceutical sectors by advancing innovative cancer therapies. With its headquarters situated in South San Francisco, California, the company plays a vital role in the burgeoning field of immune-oncology, which has become a key area of focus for new cancer treatments. The promising preclinical and clinical trials spearheaded by Alx Oncology not only highlight the company's commitment to improving cancer outcomes but also enhance its position within the competitive biotech landscape.